Kenvue Acquired by Kimberly-Clark in a Major Deal

Kenvue, recently in the spotlight following claims linking Tylenol to autism by the Trump administration, has been acquired by Kimberly-Clark in a deal valued at several billion dollars.

In a press release issued Monday, it was announced that Kimberly-Clark will purchase all outstanding shares of Kenvue common stock in a cash and stock transaction that values the company around $48.7 billion.

Notably, just last week, Texas Attorney General Ken Paxton filed a lawsuit against Kenvue and its previous parent company, Johnson & Johnson.

“We’re thrilled to merge two iconic companies to form a global leader in health and wellness,” said Mike Hsu, Chairman and CEO of Kimberly-Clark. He added, “We anticipate that the integration of our teams will bring meaningful value to our shareholders.”

Kirk Perry, CEO of Kenvue, remarked, “Joining forces with Kimberly-Clark unites two complementary portfolios, featuring cherished brands that people depend on daily.”

While this merger advances, concerns persist regarding the allegations that prenatal use of Tylenol may be linked to autism—a narrative gaining traction among certain political leaders, including those from the Trump administration. Kenvue is facing increased scrutiny in this context.

In Paxton’s lawsuit, he claimed, “Johnson & Johnson attempted to evade responsibility by unlawfully transferring liability onto another firm,” referring to Kenvue.

Currently, Kimberly-Clark’s portfolio, which includes famous brands such as Huggies, Kleenex, and Depend, will integrate with Kenvue’s offerings, including well-known names like Aveeno, Band-Aid, and Tylenol.

Reports indicated that Kimberly-Clark’s shares dropped by 15% before the market opened, whereas Kenvue’s shares surged by over 20%.

A request for comment from Kimberly-Clark by Blaze News went unanswered.